Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who ...

FX-909 is a small molecule PPARG inhibitor targeting advanced urothelial carcinoma, with a focus on patients with high PPARG expression. The phase 1B trial will evaluate safety, tolerability, and ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

The 2025 AUA Census documents significant geographic maldistribution of the urologic workforce—with 62% of US counties lacking a urologist—alongside a median practitioner age of 54 and generational ...

Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC. PATAPSCO was designed as a US-based ...

In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.

In the following interview, conducted at the 2026 American Urological Association Annual Meeting in Washington, DC, Sarah P. Psutka, MD, MSc, reflects on her talk regarding frailty and surgical ...

EMBARK enrolled 1068 men with high-risk BCR post-local therapy, conventional-imaging M0 status, PSA ≥1 ng/mL post-prostatectomy or ≥2 ng/mL above post-EBRT nadir, and PSADT ≤9 months. A protocolized ...

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD. Results of a large phase 3 study support the use of ...

CaverSTIM is an investigational device for ED post prostatectomy, implanted during surgery to restore erectile function via neuromodulation. The pilot study at Johns Hopkins University will enroll 20 ...

Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer. In an ...

In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. Jonathan ...